MOSCOW (Reuters) - Post-registration trials of Russia’s second COVID-19 vaccine, being developed by Siberia’s Vector institute, are expected to start on Nov. 15, Deputy Prime Minister Tatiana Golikova said in comments published on Wednesday.
Golikova said Russia was planning to produce 500,000 doses of its main Sputnik V vaccine in November, lower than a previous forecast of 800,000 doses given by trade and industry minister Denis Manturov.
The December forecast of 1.5 million doses remained unchanged. Golikova said Russia expected to produce 6 million monthly doses from April 2021.
